News
Thu, 10 Aug 2023 06:00:00 -0400
Thu, 10 Aug 2023 06:00:00 -0400
Financial report for the period 1 January 2023 to 30 June 2023
|
PROFIT AND LOSS |
H1 2023 |
H1 2022 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
15,633 |
12,238 |
29% |
30% |
|
Operating profit |
7,099 |
5,515 |
30% |
32% |
|
|
|
|
|
|
|
Net profit |
5,698 |
4,044 |
43% |
N/A |
|
Diluted earnings per share (in USD) |
2.53 |
1.77 |
44% |
N/A |
* CER: Constant exchange rates (average 2022).
**For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.0 = DKK 6.88720 and the period-end exchange rate of USD 1.0 = DKK 6.85386.
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the sales growth in the first half of 2023. The growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before. The performance in the first six months has enabled us to raise the outlook for the full year. Within R&D, we are very excited about the results from the SELECT trial. Obesity is a serious chronic disease associated with many comorbidities and the results from SELECT demonstrate that comorbidities associated with the condition can be significantly reduced by treating people with semaglutide.
On 10 August 2023 at 13.00 CEST, corresponding to 07.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.